Literature DB >> 27050783

The Incidence and Evolution of Parkinsonian Rigidity in Rett Syndrome: A Pilot Study.

Peter Humphreys1, Nick Barrowman2.   

Abstract

BACKGROUND: Patients with Rett syndrome (RTT) may demonstrate parkinsonian features. Here, we report a preliminary cross-sectional and prospective evaluation of the evolution, regional distribution, and eventual incidence of rigid tone in a cohort of MECP2 mutation-positive patients.
METHODS: In 51 participants, muscle tone rigidity in extremity regions and neck plus hypomimia were quantified using an RTT rigidity distribution (RTTRD) score with a range of 0 to 15. RTTRD scores were correlated with age, ability to walk and speak, mutation type, and, in a small subgroup (n=9), cerebrospinal fluid (CSF) homovanillic acid (HVA) and 5-hydroxyindole-acetic acid levels.
RESULTS: Participant ages ranged from 2 years and 5 months, to 54 years. Rigidity was found in 43/51 (84.3%); it appeared as early as age 3, increased in extent with age, and was present in all participants aged ≥13. Ankle region rigidity appeared first, followed by proximal legs, arms, neck, and face. Ambulatory participants (n=21) had lower RTTRD scores than nonambulatory (n=30; p=0.003). We found a trend to lower scores in participants with retained speech (n=13) versus those with none (n=38; p=0.074), and no difference in scores for those with truncating (n=25) versus missense mutations (n=22; p=0.387). RTTRD scores correlated negatively with CSF HVA levels (R=-0.83; p=0.005), but not with 5-hydroxyindole-acetic acid levels (R=-0.45; p=0.22).
CONCLUSIONS: Although assessment of muscle tone is somewhat subjective and the RTTRD has not been validated, this study nevertheless suggests that parkinsonian rigidity in RTT is common and frequently increases in extent with age; its severity correlates directly with impaired ambulation and inversely with CSF HVA levels.

Entities:  

Keywords:  Dopamine; HVA; MECP2; Rett syndrome; dystonia; parkinsonism

Mesh:

Substances:

Year:  2016        PMID: 27050783     DOI: 10.1017/cjn.2016.8

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  6 in total

1.  Quantification of walking-based physical activity and sedentary time in individuals with Rett syndrome.

Authors:  Jenny Downs; Helen Leonard; Kingsley Wong; Nikki Newton; Kylie Hill
Journal:  Dev Med Child Neurol       Date:  2017-02-06       Impact factor: 5.449

2.  Consensus guidelines on managing Rett syndrome across the lifespan.

Authors:  Cary Fu; Dallas Armstrong; Eric Marsh; David Lieberman; Kathleen Motil; Rochelle Witt; Shannon Standridge; Paige Nues; Jane Lane; Tristen Dinkel; Monica Coenraads; Jana von Hehn; Mary Jones; Katie Hale; Bernhard Suter; Daniel Glaze; Jeffrey Neul; Alan Percy; Timothy Benke
Journal:  BMJ Paediatr Open       Date:  2020-09-13

Review 3.  Multisystem comorbidities in classic Rett syndrome: a scoping review.

Authors:  Cary Fu; Dallas Armstrong; Eric Marsh; David Lieberman; Kathleen Motil; Rochelle Witt; Shannon Standridge; Jane Lane; Tristen Dinkel; Mary Jones; Katie Hale; Bernhard Suter; Daniel Glaze; Jeffrey Neul; Alan Percy; Timothy Benke
Journal:  BMJ Paediatr Open       Date:  2020-09-22

Review 4.  Movement disorders in patients with Rett syndrome: A systematic review of evidence and associated clinical considerations.

Authors:  Jatinder Singh; Evamaria Lanzarini; Nardo Nardocci; Paramala Santosh
Journal:  Psychiatry Clin Neurosci       Date:  2021-10-21       Impact factor: 12.145

Review 5.  Neurobiologically-based treatments in Rett syndrome: opportunities and challenges.

Authors:  Walter E Kaufmann; Jennifer L Stallworth; David B Everman; Steven A Skinner
Journal:  Expert Opin Orphan Drugs       Date:  2016-09-10       Impact factor: 0.694

Review 6.  Intellectual disability: dendritic anomalies and emerging genetic perspectives.

Authors:  Tam T Quach; Harrison J Stratton; Rajesh Khanna; Pappachan E Kolattukudy; Jérome Honnorat; Kathrin Meyer; Anne-Marie Duchemin
Journal:  Acta Neuropathol       Date:  2020-11-23       Impact factor: 17.088

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.